H
Huamao Pharmaceutical
Pharmaceutical ingredients and bioactives via synthetic biology.
About Huamao Pharmaceutical
Shanghai Huamao Pharmaceutical Co., Ltd., established in 1999, is a biopharmaceutical company located in Shanghai's Xinzhuang Industrial Park. The company is operated under the leadership of individuals including legal representative Wei Xiangchun and chairman Wei Zhe. What began as a specialized producer of pharmaceutical ingredients has evolved into a high-tech enterprise leveraging synthetic biology for a wide range of applications.
The company's history is marked by consistent growth and recognition. It was reportedly the first enterprise in China to produce medicinal lactose. Key milestones include receiving support from the Ministry of Science and Technology's innovation fund in 2003, achieving GMP certification in 2004 and renewing it in 2015, and being named a Shanghai high-tech enterprise in 2018. In June 2026, Consun Pharmaceutical announced a significant investment to acquire a 30% stake in Huamao, positioning it as a strategic associate and reinforcing its role as a key supplier.
Huamao's foundational business is the production of active pharmaceutical ingredients (APIs) and excipients. Its main products include a series of Dextran grades and USP-grade Lactose Monohydrate. Dextran 40 serves as a plasma expander in medical therapies, while other Dextran products have applications in bioscience and cryopreservation. The company's Lactose Monohydrate is a widely used excipient in pharmaceutical formulations, valued for its stability and cost-effectiveness. The firm utilizes an advanced membrane separation production process for its Dextran, which it has patented.
Building on its expertise in biopolysaccharides, the company has diversified into synthetic biology to produce high-value bioactive ingredients for the health and beauty sectors. This expanded portfolio includes substances like hydroxytyrosol, ectoine, ergothioneine, and salidroside. This strategic shift extends its business model from a B2B ingredient supplier to include OEM/ODM services, with an ambition to build an integrated industry chain from raw materials to consumer products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2026 | $26M | $105M | Consun | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Huamao Pharmaceutical in the Minhang District ecosystem
The Huamao Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Consun
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Huamao Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Huamao Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








